{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:06Z","timestamp":1784160006354,"version":"3.55.0"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"77","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,10,2]]},"DOI":"10.18632\/oncotarget.26130","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T15:10:33Z","timestamp":1538493033000},"page":"34495-34505","source":"Crossref","is-referenced-by-count":10,"title":["Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation"],"prefix":"10.18632","volume":"9","author":[{"given":"Gautam","family":"Adhikary","sequence":"first","affiliation":[{"name":"Departments of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grun","sequence":"additional","affiliation":[{"name":"Departments of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Richard","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Surgery and Division of General and Surgical Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Departments of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Keillor","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Ottawa, Ottawa, ON, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaveera","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Department of Surgery and Division of General and Surgical Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Eckert","sequence":"additional","affiliation":[{"name":"Departments of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Reproductive Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,10,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-014-2029-1","article-title":"Advances in malignant peritoneal mesothelioma","volume":"30","author":"Yu","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdl060","article-title":"Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference","volume":"17","author":"Pass","year":"2006","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"e52825","DOI":"10.1371\/journal.pone.0052825","article-title":"Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis","volume":"7","author":"Alexander","year":"2012","journal-title":"PLoS One"},{"key":"5","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1074\/jbc.273.4.2288","article-title":"Modulation of theactivity of tissue transglutaminase by calcium and GTP","volume":"273","author":"Johnson","year":"1998","journal-title":"J Biol Chem"},{"key":"6","first-page":"1909","article-title":"Tissue transglutaminase promotes or suppresses tumors depending on cell context","volume":"29","author":"Mehta","year":"2009","journal-title":"Anticancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"e20701","DOI":"10.1371\/journal.pone.0020701","article-title":"Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells","volume":"6","author":"Mehta","year":"2011","journal-title":"PLoS One"},{"key":"8","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr3085","article-title":"Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells","volume":"14","author":"Mehta","year":"2012","journal-title":"Breast Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0968-0004(02)02182-5","article-title":"Transglutaminase 2: an enigmatic enzyme with diverse functions","volume":"27","author":"Piacentini","year":"2002","journal-title":"Trends Biochem Sci"},{"key":"10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mc.22375","article-title":"Transglutaminase is a tumor cell and cancer stem cell survival factor","volume":"54","author":"Kerr","year":"2015","journal-title":"Mol Carcinog"},{"key":"11","doi-asserted-by":"publisher","first-page":"20525","DOI":"10.18632\/oncotarget.3890","article-title":"Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition","volume":"6","author":"Eckert","year":"2015","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1158\/0008-5472.CAN-16-2032","article-title":"Transglutaminase interaction with a6\/b4-integrin to stimulates YAP1-dependent DNp63a stabilization and leads to enhanced cancer stem cell survival and tumor formation","volume":"76","author":"Eckert","year":"2016","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1111\/j.1742-4658.2011.08346.x","article-title":"Extracellular TG2: emerging functions and regulation","volume":"278","author":"Belkin","year":"2011","journal-title":"FEBS J"},{"key":"14","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1158\/0008-5472.CAN-06-2387","article-title":"Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis","volume":"66","author":"Mehta","year":"2006","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-008-9642-1","article-title":"Tissue transgluaminase 2 expression in meningiomas","volume":"90","author":"Rich","year":"2008","journal-title":"J Neurooncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-07-0307","article-title":"Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase","volume":"67","author":"Matei","year":"2007","journal-title":"Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00432-009-0681-6","article-title":"Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer","volume":"136","author":"Hong","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.bcp.2010.06.029","article-title":"Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer","volume":"80","author":"Kim","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"19","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.1158\/1078-0432.CCR-04-1107","article-title":"Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00726-011-1167-9","article-title":"Tissue transglutaminase: a new target to reverse cancer drug resistance","volume":"44","author":"Di","year":"2013","journal-title":"Amino Acids"},{"key":"21","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/sj.onc.1210035","article-title":"Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells","volume":"26","author":"Mehta","year":"2007","journal-title":"Oncogene"},{"key":"22","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/bcr3034","article-title":"Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells","volume":"13","author":"Lee","year":"2011","journal-title":"Breast Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/carcin\/bgm280","article-title":"The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer","volume":"29","author":"Brown","year":"2008","journal-title":"Carcinogenesis"},{"key":"24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drup.2007.06.002","article-title":"Tissue transglutaminase-mediated chemoresistance in cancer cells","volume":"10","author":"Mehta","year":"2007","journal-title":"Drug Resist Updat"},{"key":"25","doi-asserted-by":"crossref","first-page":"e13390","DOI":"10.1371\/journal.pone.0013390","article-title":"Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells","volume":"5","author":"Mehta","year":"2010","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1158\/0008-5472.CAN-09-1257","article-title":"Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase","volume":"69","author":"Matei","year":"2009","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/onc.2011.429","article-title":"Tissue transglutaminase links TGF-\u03b2, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer","volume":"31","author":"Matei","year":"2012","journal-title":"Oncogene"},{"key":"28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1152\/physrev.00019.2013","article-title":"Transglutaminase regulation of cell function","volume":"94","author":"Mehta","year":"2014","journal-title":"Physiol Rev"},{"key":"29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ijc.2910580316","article-title":"High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells","volume":"58","author":"Mehta","year":"1994","journal-title":"Int J Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10577-006-1069-y","article-title":"From genetics to epigenetics: the tale of Polycomb group and trithorax group genes","volume":"14","author":"Cavalli","year":"2006","journal-title":"Chromosome Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"van Lohuizen","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tips.2014.10.014","article-title":"Inhibitors of tissue transglutaminase","volume":"36","author":"Akbar","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"33","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1038\/onc.2016.452","article-title":"Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival","volume":"36","author":"Eckert","year":"2017","journal-title":"Oncogene"},{"key":"34","doi-asserted-by":"crossref","first-page":"e0119549","DOI":"10.1371\/journal.pone.0119549","article-title":"Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents","volume":"10","author":"Filimonenko","year":"2015","journal-title":"PLoS One"},{"key":"35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","article-title":"Identification of cancer stem cell markers in human malignant mesothelioma cells","volume":"404","author":"Morimoto","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"36","doi-asserted-by":"crossref","first-page":"e84324","DOI":"10.1371\/journal.pone.0084324","article-title":"Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation","volume":"8","author":"Eckert","year":"2013","journal-title":"PLoS One"},{"key":"37","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.bbagen.2012.07.002","article-title":"Biochemistry of epidermal stem cells","volume":"1830","author":"Kerr","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"38","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1038\/onc.2015.507","article-title":"VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors","volume":"35","author":"Eckert","year":"2016","journal-title":"Oncogene"},{"key":"39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-14-0685-T","article-title":"Transglutaminase is required for epidermal squamous cell carcinoma stem cell survival","volume":"13","author":"Kerr","year":"2015","journal-title":"Mol Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1172\/JCI71605","article-title":"Cancer epigenetics drug discovery and development: the challenge of hitting the mark","volume":"124","author":"Tummino","year":"2014","journal-title":"J Clin Invest"},{"key":"41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrc2931","article-title":"Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins","volume":"10","author":"Mills","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/carcin\/bgv064","article-title":"Survival of skin cancer stem cells requires the Ezh2 polycomb group protein","volume":"36","author":"Eckert","year":"2015","journal-title":"Carcinogenesis"},{"key":"43","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/mc.22448","article-title":"The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane","volume":"55","author":"Eckert","year":"2016","journal-title":"Mol Carcinog"},{"key":"44","doi-asserted-by":"crossref","first-page":"e2592","DOI":"10.1038\/cddis.2017.30","article-title":"Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia","volume":"8","author":"Moro","year":"2017","journal-title":"Cell Death Dis"},{"key":"45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1139\/v08-024","article-title":"The bioorganic chemistry of transglutaminase - from mechanism to inhibition and engineering","volume":"86","author":"Lubell","year":"2008","journal-title":"Can J Chem"},{"key":"46","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.1021\/acs.jmedchem.7b01070","article-title":"Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase","volume":"60","author":"Keillor","year":"2017","journal-title":"J Med Chem"},{"key":"47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/bcr3371","article-title":"Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer","volume":"15","author":"Mehta","year":"2013","journal-title":"Breast Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1158\/0008-5472.CAN-06-1457","article-title":"Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway","volume":"66","author":"Mehta","year":"2006","journal-title":"Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.25555","article-title":"Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma","volume":"117","author":"Alexander","year":"2011","journal-title":"Cancer"}],"updated-by":[{"DOI":"10.18632\/oncotarget.28793","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"record-id":"71549"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T19:37:07Z","timestamp":1589053027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,2]]},"references-count":49,"journal-issue":{"issue":"77","published-print":{"date-parts":[[2018,10,2]]}},"alternative-id":["26130","30349644"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26130","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,2]]}}}